Ambrx Biopharma American Stock Current Liabilities
| AMAMDelisted Stock | USD 15.73 0.71 4.73% |
Ambrx Biopharma American fundamentals help investors to digest information that contributes to Ambrx Biopharma's financial success or failures. It also enables traders to predict the movement of Ambrx Stock. The fundamental analysis module provides a way to measure Ambrx Biopharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Ambrx Biopharma stock.
Ambrx |
Ambrx Biopharma American Company Current Liabilities Analysis
Ambrx Biopharma's Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
CompetitionIn accordance with the recently published financial statements, Ambrx Biopharma American has a Current Liabilities of 0.0. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The current liabilities for all United States stocks is 100.0% higher than that of the company.
Ambrx Current Liabilities Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Ambrx Biopharma's direct or indirect competition against its Current Liabilities to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Ambrx Biopharma could also be used in its relative valuation, which is a method of valuing Ambrx Biopharma by comparing valuation metrics of similar companies.Ambrx Biopharma is currently under evaluation in current liabilities category among its peers.
Ambrx Fundamentals
| Return On Equity | -0.37 | |||
| Return On Asset | -0.19 | |||
| Operating Margin | (483.51) % | |||
| Current Valuation | 1.56 B | |||
| Shares Outstanding | 63.29 M | |||
| Shares Owned By Insiders | 2.09 % | |||
| Shares Owned By Institutions | 97.91 % | |||
| Number Of Shares Shorted | 1.16 M | |||
| Price To Earning | 0.19 X | |||
| Price To Book | 7.31 X | |||
| Price To Sales | 432.96 X | |||
| Revenue | 4.09 M | |||
| Gross Profit | 7.4 M | |||
| EBITDA | (61.75 M) | |||
| Net Income | (67.06 M) | |||
| Cash And Equivalents | 110.89 M | |||
| Cash Per Share | 2.87 X | |||
| Total Debt | 11.98 M | |||
| Debt To Equity | 0.09 % | |||
| Current Ratio | 4.70 X | |||
| Book Value Per Share | 3.85 X | |||
| Cash Flow From Operations | (57.7 M) | |||
| Short Ratio | 1.21 X | |||
| Earnings Per Share | 0.42 X | |||
| Price To Earnings To Growth | (0.15) X | |||
| Target Price | 28.5 | |||
| Number Of Employees | 87 | |||
| Beta | -2.36 | |||
| Market Capitalization | 1.77 B | |||
| Total Asset | 146.98 M | |||
| Retained Earnings | (291.63 M) | |||
| Working Capital | 73.92 M | |||
| Z Score | 85.23 | |||
| Net Asset | 146.98 M |
About Ambrx Biopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Ambrx Biopharma American's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ambrx Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ambrx Biopharma American based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Other Consideration for investing in Ambrx Stock
If you are still planning to invest in Ambrx Biopharma American check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Ambrx Biopharma's history and understand the potential risks before investing.
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk |